Reduced CCR5 expression among Uganda HIV controllers

[1]  T. Cokelaer,et al.  Low CCR5 expression protects HIV-specific CD4+ T cells of elite controllers from viral entry , 2022, Nature communications.

[2]  P. Ive,et al.  Reduced CCR5 Expression and Immune Quiescence in Black South African HIV-1 Controllers , 2021, Frontiers in Immunology.

[3]  M. Nolan,et al.  Prevalence of undetectable and suppressed viral load in HIV-infected pregnant women initiating Option B+ in Uganda: an observational study nested within a randomized controlled trial , 2021, BMC Infectious Diseases.

[4]  O. J. Sande,et al.  Variations in Trim5α and Cyclophilin A genes among HIV-1 elite controllers and non controllers in Uganda: a laboratory-based cross-sectional study , 2019, Retrovirology.

[5]  P. Klenerman,et al.  Maintenance of Functional CD57+ Cytolytic CD4+ T Cells in HIV+ Elite Controllers , 2019, Front. Immunol..

[6]  O. Pornillos,et al.  Restriction of HIV-1 and other retroviruses by TRIM5 , 2019, Nature Reviews Microbiology.

[7]  R. Mehlotra.  CCR5 Promoter Polymorphism −2459G > A: Forgotten or Ignored? , 2019, Cells.

[8]  B. Walker,et al.  Transcriptional down-regulation of ccr5 in a subset of HIV+ controllers and their family members , 2019, eLife.

[9]  B. Bagaya,et al.  Brief Report: Identification of Elite and Viremic Controllers From a Large Urban HIV Ambulatory Center in Kampala, Uganda , 2018, Journal of acquired immune deficiency syndromes.

[10]  H. Garg,et al.  CCR5 promoter activity correlates with HIV disease progression by regulating CCR5 cell surface expression and CD4 T cell apoptosis , 2017, Scientific Reports.

[11]  V. Appay,et al.  TCR clonotypes: molecular determinants of T-cell efficacy against HIV. , 2016, Current opinion in virology.

[12]  Samit R. Joshi,et al.  Increased Levels of Macrophage Inflammatory Proteins Result in Resistance to R5-Tropic HIV-1 in a Subset of Elite Controllers , 2015, Journal of Virology.

[13]  I. Joosten,et al.  The number of CCR5 expressing CD4+ T lymphocytes is lower in HIV-infected long-term non-progressors with viral control compared to normal progressors: a cross-sectional study , 2014, BMC Infectious Diseases.

[14]  M. Potgieter,et al.  Mutations in C-C chemokine receptor type 5 (CCR5) in South African individuals. , 2013, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[15]  Hualiang Jiang,et al.  Structure of the CCR5 Chemokine Receptor–HIV Entry Inhibitor Maraviroc Complex , 2013, Science.

[16]  B. Walker,et al.  Unravelling the mechanisms of durable control of HIV-1 , 2013, Nature Reviews Immunology.

[17]  H. Mitsuya,et al.  CCR5 inhibitors: emergence, success, and challenges , 2012, Expert opinion on emerging drugs.

[18]  Jack T Stapleton,et al.  The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation , 2010, Science.

[19]  Jeffrey N. Martin,et al.  HIV Controllers with HLA-DRB1*13 and HLA-DQB1*06 Alleles Have Strong, Polyfunctional Mucosal CD4+ T-Cell Responses , 2010, Journal of Virology.

[20]  V. Simon,et al.  Immune mechanisms of HIV control. , 2010, Current opinion in immunology.

[21]  C. Tiemessen,et al.  Genetic variation within the gene encoding the HIV-1 CCR5 coreceptor in two South African populations , 2010, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[22]  N. Sewankambo,et al.  Frequency of Long-Term Nonprogressors in HIV-1 Seroconverters From Rakai Uganda , 2009, Journal of acquired immune deficiency syndromes.

[23]  M. Hughes,et al.  Associations of Chemokine Receptor Polymorphisms With HIV-1 Mother-to-Child Transmission in Sub-Saharan Africa: Possible Modulation of Genetic Effects by Antiretrovirals , 2008, Journal of acquired immune deficiency syndromes.

[24]  Terri Wrin,et al.  Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. , 2008, The Journal of infectious diseases.

[25]  M. Batzer,et al.  Distribution of the HIV resistance CCR5-Δ32 allele among Egyptians and Syrians , 2007 .

[26]  Roger Detels,et al.  Effects of human TRIM5α polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection , 2006 .

[27]  M. McElrath,et al.  Combined Effect of CCR5-Δ32 Heterozygosity and the CCR5 Promoter Polymorphism −2459 A/G on CCR5 Expression and Resistance to Human Immunodeficiency Virus Type 1 Transmission , 2005, Journal of Virology.

[28]  V. Soriano,et al.  Association of CCR5 human haplogroup E with rapid HIV type 1 disease progression. , 2005, AIDS research and human retroviruses.

[29]  M. Lederman,et al.  CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro. , 2003, Clinical immunology.

[30]  M. Lederman,et al.  R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Eugen-Olsen,et al.  Adverse effect of the CCR5 promoter −2459A allele on HIV‐1 disease progression , 2001, Journal of medical virology.

[32]  M. Picot,et al.  CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression , 2001, AIDS.

[33]  S. Rowland-Jones,et al.  CCR5 promoter polymorphisms in a Kenyan perinatal human immunodeficiency virus type 1 cohort: association with increased 2-year maternal mortality. , 2001, The Journal of infectious diseases.

[34]  S. O’Brien,et al.  Influence of CCR5 promoter haplotypes on AIDS progression in African–Americans , 2000, AIDS.

[35]  Y. Yan,et al.  Influence of nucleotide polymorphisms in the CCR2 gene and the CCR5 promoter on the expression of cell surface CCR5 and CXCR4. , 2000, International immunology.

[36]  A. J. Valente,et al.  Evolution of Human and Non-human Primate CC Chemokine Receptor 5 Gene and mRNA , 2000, The Journal of Biological Chemistry.

[37]  B. Korber,et al.  A Polymorphism in the Regulatory Region of the CC-Chemokine Receptor 5 Gene Influences Perinatal Transmission of Human Immunodeficiency Virus Type 1 to African-American Infants , 1999, Journal of Virology.

[38]  R. Bertorelle,et al.  Analysis of the CC chemokine receptor 5 m303 mutation in infants born to HIV-1-seropositive mothers. , 1999, AIDS.

[39]  J. Goedert,et al.  Genetic acceleration of AIDS progression by a promoter variant of CCR5. , 1998, Science.

[40]  C. Kleeberger,et al.  CCR5 promoter polymorphism and HIV-1 disease progression , 1998, The Lancet.

[41]  P. O’Connell,et al.  Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression , 1998, Nature Medicine.

[42]  H. Schuitemaker,et al.  The role of a stromal cell‐derived factor‐1 chemokine gene variant in the clinical course of HIV‐1 infection , 1998, AIDS.

[43]  Luc Montagnier,et al.  HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene , 1998, The Lancet.

[44]  M. Carrington,et al.  Novel alleles of the chemokine-receptor gene CCR5. , 1997, American journal of human genetics.

[45]  A. Blauvelt,et al.  Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: Implications for HIV primary infection , 1997, Nature Medicine.

[46]  M. Metzker,et al.  The extent of genetic variation in the CCR5 gene , 1997, Nature Genetics.

[47]  Virginia Litwin,et al.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.

[48]  Stephen C. Peiper,et al.  Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.

[49]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[50]  D. Weissman,et al.  Inherited Resistance to HIV-1 Conferred by an Inactivating Mutation in CC Chemokine Receptor 5: Studies in Populations with Contrasting Clinical Phenotypes, Defined Racial Background, and Quantified Risk , 1997, Molecular medicine.